These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

359 related items for PubMed ID: 12664069

  • 1. Effects of combination therapy with a luteinizing hormone-releasing hormone agonist and chlormadinone acetate on rat prostate weight and plasma testosterone levels.
    Gotanda K, Shinbo A, Okada M, Nakano Y, Kobayashi H, Sasaki T, Hagiwara M, Akaza H.
    Prostate Cancer Prostatic Dis; 2003; 6(1):66-72. PubMed ID: 12664069
    [Abstract] [Full Text] [Related]

  • 2. Suppressive effects of the antiandrogen agent, chlormadinone acetate and the 5alpha-reductase inhibitor, dutasteride on prostate weight and intraprostatic androgen levels in rats.
    Kobayashi H, Gotanda K, Shibata Y, Watanabe J, Nakano Y, Shinbo A, Suzuki K.
    Arzneimittelforschung; 2011; 61(9):515-20. PubMed ID: 22029228
    [Abstract] [Full Text] [Related]

  • 3. [Pretreatment with chlormadinone acetate in prostate cancer patients treated with a luteinizing hormone-releasing hormone analogue].
    Yamamoto A, Sumiyoshi Y, Miyake N, Yokozeki H, Kanayama H, Kagawa S.
    Hinyokika Kiyo; 1998 Aug; 44(8):557-63. PubMed ID: 9783191
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of disease flare with diethylstilbestrol diphosphate and chlormadinone acetate administration for two weeks prior to slow-releasing leuprolide acetate in prostatic cancer patients.
    Ohuchi H, Noguchi K, Kinoshita Y, Hosaka M, Kawasaki C, Miura T, Kondo I, Harada M.
    Hinyokika Kiyo; 2000 Aug; 46(8):531-6. PubMed ID: 11019371
    [Abstract] [Full Text] [Related]

  • 5. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
    Lamberts SW, Uitterlinden P, de Jong FH.
    Cancer Res; 1988 Nov 01; 48(21):6063-8. PubMed ID: 2844399
    [Abstract] [Full Text] [Related]

  • 6. Decrease of genital organ weights and plasma testosterone levels in rats following oral administration of leuprolide microemulsion.
    Zheng JY, Fulu MY.
    Int J Pharm; 2006 Jan 13; 307(2):209-15. PubMed ID: 16300912
    [Abstract] [Full Text] [Related]

  • 7. Prevention of the initial testosterone surge induced by a luteinizing hormone-releasing hormone analogue in prostate cancer patients: the endocrinological effects of pretreatment with chlormadinone acetate.
    Yamamoto A, Sumiyoshi Y, Miyake N, Yokozeki H, Kanayama H, Kagawa S.
    J Med Invest; 1999 Feb 13; 46(1-2):55-8. PubMed ID: 10408158
    [Abstract] [Full Text] [Related]

  • 8. [Clinical study on chlormadinone acetate alone followed by combination with LH-RH analogue for prostatic cancer: effects on lipid metabolism].
    Shimada M, Uchida H, Kasahara T, Fuji K, Ogawa Y, Yoshida H, Hamajima T, Matsuda N, Ikeuchi T, Kai Y, Hiramori M, Hoshino M, Inoue K, Higaki Y.
    Hinyokika Kiyo; 1998 Jul 13; 44(7):525-32. PubMed ID: 9752613
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of testosterone production with ketoconazole alone and in combination with a gonadotropin releasing hormone analogue in the rat.
    English HF, Santner SJ, Levine HB, Santen RJ.
    Cancer Res; 1986 Jan 13; 46(1):38-42. PubMed ID: 3079588
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the effects of chlormadinone acetate-pellet implantation and orchidectomy on benign prostatic hypertrophy in the dog.
    Kawakami E, Tsutsui T, Shimizu M, Orima H, Fujita M, Ogasa A.
    Int J Androl; 1995 Oct 13; 18(5):248-55. PubMed ID: 8567095
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by leuprorelin, a luteinizing hormone-releasing hormone agonist.
    Said MM, Hokaiwado N, Tang M, Ogawa K, Suzuki S, Ghanem HM, Esmat AY, Asamoto M, Refaie FM, Shirai T.
    Cancer Sci; 2006 Jun 13; 97(6):459-67. PubMed ID: 16734723
    [Abstract] [Full Text] [Related]

  • 12. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS, Pacificar JS, Shapiro CE, Williams SG.
    J Urol; 2007 Jun 13; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [Abstract] [Full Text] [Related]

  • 13. [Hormonal environment following treatment with a small dose of estrogen--small dose of estrogen alone and in combination with an anti-androgen].
    Hayashi T, Taki Y, Ikai K, Hiura M, Kiriyama T.
    Hinyokika Kiyo; 1987 Jul 13; 33(7):1035-42. PubMed ID: 2446483
    [Abstract] [Full Text] [Related]

  • 14. Effect of antiandrogen, chlormadinone acetate (CMA), in canine spontaneous benign prostatic hyperplasia (BPH).
    Murakoshi M, Ikada R, Tagawa M, Nakayama T.
    Tokai J Exp Clin Med; 2000 Apr 13; 25(1):11-4. PubMed ID: 11023050
    [Abstract] [Full Text] [Related]

  • 15. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Kaku H, Saika T, Tsushima T, Ebara S, Senoh T, Yamato T, Nasu Y, Kumon H.
    Prostate; 2006 Mar 01; 66(4):439-44. PubMed ID: 16329145
    [Abstract] [Full Text] [Related]

  • 16. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
    Sakai H, Igawa T, Tsurusaki T, Yura M, Kusaba Y, Hayashi M, Iwasaki S, Hakariya H, Hara T, Kanetake H.
    Urology; 2009 Mar 01; 73(3):635-40. PubMed ID: 19038426
    [Abstract] [Full Text] [Related]

  • 17. Pharmacologic profiles of investigational kisspeptin/metastin analogues, TAK-448 and TAK-683, in adult male rats in comparison to the GnRH analogue leuprolide.
    Matsui H, Masaki T, Akinaga Y, Kiba A, Takatsu Y, Nakata D, Tanaka A, Ban J, Matsumoto S, Kumano S, Suzuki A, Ikeda Y, Yamaguchi M, Watanabe T, Ohtaki T, Kusaka M.
    Eur J Pharmacol; 2014 Jul 15; 735():77-85. PubMed ID: 24747751
    [Abstract] [Full Text] [Related]

  • 18. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T, Nishizawa K, Mitsumori K.
    Scand J Urol Nephrol; 2006 Jul 15; 40(3):198-203. PubMed ID: 16809259
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and pharmacodynamics of a parenteral testosterone microsphere formulation in the male rat. Demonstration of dose dependence and controlled release.
    Peacock NR, Swerdloff RS, Berman N, Gilley RM, Tice TR, Bhasin S.
    J Androl; 1993 Jul 15; 14(1):45-52. PubMed ID: 8473236
    [Abstract] [Full Text] [Related]

  • 20. Histopathological and immunocytochemical studies of chlormadinone acetate on the rat prostate.
    Murakoshi M, Ikeda R, Fukui N, Tagawa M.
    Tokai J Exp Clin Med; 2002 Dec 15; 27(4):91-5. PubMed ID: 12713012
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.